Antipsychotic dosing and concurrent psychotropic treatments for medicaid-insured individuals with schizophrenia

Schizophrenia Bulletin

Volumn 28, Issue 4, 2002, Pages 607-617

  DosReis, Susan ^a   Zito, Julie Magno ^b   Buchanan, Robert W ^b   Lehman, Anthony F ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic dosage; Concurrent pharmacotherapy; Medicaid; Pharmacoepidemiology; Schizophrenia; Schizophrenia Patient Outcomes Research Team

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; MESORIDAZINE; NEUROLEPTIC AGENT; SEDATIVE AGENT; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGE; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG POTENCY; ETHNOLOGY; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTPATIENT CARE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA;

EID: 0037989711     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006968     Document Type: Article

References (33)

1. Ascione, F.J.; Brown, G.H.; and Kirking, D.M. Evaluation of a medication refill reminder system for a community pharmacy. Patient Education and Counseling, 7(2):157-165, 1985.
2. Aubree, J.C., and Lader, M.H. High and very high dosage antipsychotics: A critical review. Journal of Clinical Psychiatry, 41(10):341-350, 1980.
3. Baldessarini, R.J.; Cohen, B.M.; and Teicher, M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45(1):79-91, 1988.
4. Baldessarini, R.J.; Katz, B.; and Cotton, P. Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry, 141(6):748-752, 1984.
5. Bollini, P.; Pampallona, S.; Orza, M.J.; Adams, M.E.; and Chalmers, T.C. Antipsychotic drugs: Is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine, 24:307-316, 1994.
6. Buchanan, R.W., and Carpenter, W.T. Targeted maintenance treatment in schizophrenia. CNS Drugs, 5(4):240-245, 1996.
7. Cheung, F.K., and Snowden, L.R. Community mental health and ethnic minority populations. Community Mental Health Journal, 26(3):277-291, 1990.
8. Davis, J.M. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry, 33:858-861, 1976.
9. Gardos, G.; Cole, J.O.; and Orzack, M.H. The importance of dosage in antipsychotic drug administration: A review of dose-response studies. Psychopharmacologia, 29:221-230, 1973.
10. Italian Collaborative Study Group. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. European Journal of Clinical Pharmacology, 55:685-690, 1999.
11. Jeste, D.V.; Lindamer, L.A.; Evans, J.; and Lacro, J.P. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacology Bulletin, 32(2):243-251, 1996.
12. Kane, J.M. Schizophrenia. New England Journal of Medicine, 334(1):34-41, 1996.
13. Kane, J.M.; Rifkin, A.; Woerner, M.; Reardon, G.; Kreisman, D.; Blumenthal, R.; and Borenstein, M. Highdose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacology Bulletin, 21(3):533-537, 1985.
14. Kane, J.M.; Rifkin, A.; Woerner, M.; Reardon, G.; Sarantakos, S.; Schiebel, D.; and Ramos-Lorenzi, J. Low-dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry, 40:893-896, 1983.
15. Lawson, W.B.; Hepler, N.; Holladay, J.; and Cuffel, B. Race as a factor in inpatient and outpatient admissions and diagnosis. Hospital and Community Psychiatry, 45(1):72-74, 1994.
16. Lehman, A.F.; Steinwachs, D.M.; and Co-Investigators of the PORT Project. At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998.
17. McCombs, J.S.; Nichol, M.B.; Stimmel, G.L.; Shi, J.; and Smith, R.R. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. Journal of Clinical Psychiatry, 60(Suppl 19):5-11, 1999.
18. McEvoy, J.P.; Hogarty, G.E.; and Steingard, S. Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48:739-745, 1991.
19. Quitkin, F.; Rifkin, A.; and Klein, D.F. Very high dosage vs standard dosage fluphenazine in schizophrenia. Archives of General Psychiatry, 32:1276-1281, 1975.
20. Rifkin, A.; Doddi, S.; Karajgi, B.; Borenstein, M.; and Wachspress, M. Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48:166-170, 1991.
21. Rodenhauser, P.; Schwenkner, C.E.; and Khamis, H.J. Factors related to drug treatment refusal in a forensic hospital. Hospital and Community Psychiatry, 38(6):631-637, 1987.
22. Schulz, R.M., and Gagnon, J.P. Patient behavior patterns regarding prescription refills. Contemporary Pharmacy Practice, 5(3):150-155, 1982.
23. Stone, C.K.; Garver, D.L.; Griffith, J.; Hirschowitz, J.; and Bennet, J. Further evidence of dose-response threshold for haloperidol in psychosis. American Journal of Psychiatry, 152(8):1210-1212, 1995.
24. Strickland, T.L.; Ranganath, V.; Lin, K.; Poland, R.E.; Mendoza, R.; and Smith, M.W. Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacology Bulletin, 27(4):441-448, 1991.
25. Volavka, J.; Cooper, T.; Czobor, P.; Bitter, I.; Meisner, M.; Laska, E.; Gastanaga, P.; Krakowski, M.; Chou, J.; Crowner, M.; and Douyon, R. Haloperidol blood levels and clinical effects. Archives of General Psychiatry, 49:354-361, 1992.
26. Walkup, J.T.; McAlpine, D.D.; Olfson, M.; Labay, L.E.; Boyer, C.; and Hansell, S. Patients with schizophrenia at risk for excessive antipsychotic dosing. Journal of Clinical Psychiatry, 61(5):344-348, 2000.
27. Williams, C.L.; Johnstone, B.M.; Kesterson, J.G.; Javor, K.A.; and Schmetzer, A.D. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care, 37(4):AS81-AS86, 1999.
28. Williams, M.H.; Bloom, J.D.; Faulkner, L.R.; Rogers, J.L.; and Godard, S.L. Drug treatment refusal and length of hospitalization of insanity acquittees. Bulletin of the American Academy of Psychiatry and the Law, 16(3):279-284, 1988.
29. World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: A consensus statement. British Journal of Psychiatry, 156:412-414, 1990.
30. Zito, J.M., ed. Psychotherapeutic Drug Manual. New York: John Wiley and Sons, 1994.
31. Zito, J.M.; Craig, M.D.; and Wanderling, J. New York under the Rivers decision: An epidemiological study of drug treatment refusal. American Journal of Psychiatry, 148(7):904-909, 1991.
32. Zito, J.M.; Craig, T.J.; Wanderling, J.; and Siegel, C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. American Journal of Psychiatry, 144(6):778-782, 1987.
33. Zito, J.M.; Craig, T.J.; Wanderling, J.; Siegel, C.; and Green, M. Pharmacotherapy of the hospitalized young adult schizophrenic patient. Comprehensive Psychiatry, 29(4):379-386, 1988.